Ariadna Lara Gutierrez

Mrs. Ariadna Lara Gutierrez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
GPGang Pan
Gang Pan
KDKlev Diamanti
Klev Diamanti
MCMarco Cavalli
Marco Cavalli
AGAriadna Lara Gutierrez
Ariadna Lara Gutierrez
JKJan Komorowski
Jan Komorowski
CWClaes Wadelius
Claes Wadelius
Recent studies suggested that dysregulated YY1 plays a pivotal role in many liver diseases. To obtain a detailed view of genes and pathways regulated by YY1 in the liver, we carried out RNA sequencing in HepG2 cells after YY1 knockdown. A rigid set of 2,081 differentially expressed genes was identified by comparing the YY1-knockdown samples (n = 8) with the control samples (n = 14). YY1 knockdown significantly decreased the expression of several key transcription factors and their coactivators in lipid metabolism. This is illustrated by YY1 regulating PPARA expression through binding to its promoter and enhancer regions. Our study further suggest that down-regulation of the key transcription factors together with YY1 knockdown significantly decreased the cooperation between YY1 and these transcription factors at various regulatory regions, which are important in regulating the expression of genes in hepatic lipid metabolism. This was supported by the finding that the expression of SCD and ELOVL6, encoding key enzymes in lipogenesis, were regulated by the cooperation between YY1 and PPARA/RXRA complex over their promoters.

25 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AGAriadna Lara Gutierrez
Ariadna Lara Gutierrez
JLJulia Hedlund Lindberg
Julia Hedlund Lindberg
GSGanna Shevchenko
Ganna Shevchenko
IGInger Gustavsson
Inger Gustavsson
JBJonas Bergquist
Jonas Bergquist
SEStefan Enroth
Stefan Enroth
Molecular screening programs for cervical cancer detect the presence of human papilloma virus (HPV) in cell material or vaginal fluids. Persistent infection with high-risk HPV is a necessary pre-requisite, but the majority of infections do not lead to pathological states. Additional biomarkers are needed to increase the specificity of the molecular tests. Here, we have investigated the possibility of detecting protein biomarkers using mass spectrometry from dried self-sampled cervico–vaginal fluid deposited on FTA cards. We found significant intra-individual correlations (p < 2.2 × 10−16), although heterogenous protein profiles were obtained between individuals. Out of 3699 proteins found in total, 169 were detected in at least 95% of the samples. Using a discovery/replication design, 18 proteins were found to be significant in the discovery cohort, with higher values in those cases compared to controls. All of these were found to also have higher levels among the cases in the replication cohort, with one protein (DEAD-Box Helicase) remaining statistically significant. Finally, a predictive 7-protein multivariate model was developed with a sensitivity and specificity of 0.90 and 0.55, respectively. Our results demonstrate that robust measurements of protein biomarkers can be obtained from self-sampled dried CVF and that these could be used to predict cervical cancer pre-stages.

6 April 2025 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
AGAriadna Lara Gutierrez
Ariadna Lara Gutierrez
IHIris Halbwedl
Iris Halbwedl
SSStefan Sauer
Stefan Sauer
PRPeter Regitnig
Peter Regitnig
EPEdgar Petru
Edgar Petru
KKKarl Kashofer
Karl Kashofer
Genomic instability scars are markers for detecting homologous recombination deficiency status in ovarian cancer patients and predicting the response to PARP inhibitor treatment. Currently, only a few reliable and validated assays are available, with the Myriad myChoice CDx being the most commonly used commercial assay for genomic instability scar score determination; given the need for a more straightforward, accessible, and reliable method for detecting genomic instability scars methods. In this work we describe the feasibility of using the microarray OncoScan CNV assay and open-source software packages to quantify genomic instability scores, and the development of an open-access online platform for genomic instability score calculation. Our laboratory-developed test accurately classified homologous recombination-proficient and recombination-deficient samples based on genomic instability scores derived from the Oncoscan CNV assay. Internally evaluated genomic instability scores demonstrated a 92% overall agreement and a higher sample success rate compared to externally analyzed genomic instability scar scores. The availability of HRD determination has doubled the number of patients eligible for PARP therapy. The assay can be conveniently performed on individual samples, and the open-access online platform facilitates HRD determination without the need for specialized bioinformatics support.